Ynvisible Announces Strategic Partnership with Sapphiros for Exclusive Supply of E-Paper Displays for Next-Generation Diagnostic Devices
MWN-AI** Summary
On March 11, 2026, Ynvisible Interactive Inc. (TSXV: YNV) announced a significant strategic partnership with Sapphiros, a private consumer diagnostics company. The partnership involves establishing Ynvisible as the exclusive supplier of e-paper displays for certain diagnostic tests developed by Sapphiros, including lateral flow and molecular diagnostics. This collaboration is underscored by a Letter of Intent (LOI) that outlines plans for a three-year exclusive supply agreement and anticipates an acceleration of sales throughout 2026, contingent upon ongoing regulatory approvals for Sapphiros' products.
The partnership marks a pivotal expansion for Ynvisible into the rapidly growing medical diagnostics sector. It builds upon prior collaborations where Ynvisible supplied displays for laboratory testing related to various rapid diagnostic solutions aimed at point-of-care and direct-to-consumer markets. As healthcare systems increasingly move toward decentralized testing, Ynvisible's technology—known for its ultra-low power and flexible display characteristics—positions the company to play a significant role in this market transition.
Ynvisible CEO Ramin Heydarpour emphasized the importance of this LOI, stating it paves the way for the commercial deployment of their technology in next-generation diagnostic devices, while Sapphiros CEO Mark Gladwell highlighted the partnership's potential to improve access to diagnostic results for patients everywhere.
Overall, this collaboration signals exciting times ahead for Ynvisible as it leverages its innovative e-paper display technology to meet the demands of a growing diagnostics market, enhancing both accessibility and reliability of health monitoring tools. The agreement with Sapphiros is expected to lead to substantial opportunities in high-volume applications as medical diagnostics evolve.
MWN-AI** Analysis
Ynvisible Interactive Inc. (TSXV: YNV), a frontrunner in printed e-paper display technology, has announced a significant strategic partnership with Sapphiros, a consumer diagnostics firm. This collaboration positions Ynvisible as the exclusive supplier of e-paper displays for Sapphiros' upcoming diagnostic devices, unlocking substantial market opportunities in the burgeoning medical diagnostics sector.
As highlighted in the announcement, the partnership underpins an exclusive three-year supply agreement, with commercial sales expected to ramp up throughout 2026. The ongoing clinical studies and the anticipated FDA regulatory approvals for Sapphiros' Digital Lateral Flow tests signify a timely entry into a rapidly expanding market, characterized by increasing demand for decentralized and rapid diagnostic solutions.
Investors should take a close look at Ynvisible’s unique technology offerings—ultra-low power, thin, and flexible displays that require minimal electronics. These attributes are particularly appealing in medical applications, where reliability and user-friendliness are paramount. The favorable positioning within the diagnostics space aligns with global trends toward accessible healthcare, suggesting a robust revenue stream as healthcare providers and consumers seek innovative solutions.
From a strategic viewpoint, this partnership enhances Ynvisible's market diversification beyond traditional sectors. The collaboration not only validates Ynvisible's technological prowess but also solidifies its footing in high-volume medical applications, an area with significant growth potential.
Additionally, investors should note the dual-edged nature of this opportunity—while the partnership offers substantial growth prospects, it also involves inherent risks related to regulatory approvals and market adoption rates. As such, a cautious and informed approach is advisable, balancing potential high returns against the uncertainties of the healthcare innovation landscape.
In summary, Ynvisible Interactive's strategic alliance with Sapphiros presents a compelling investment opportunity in the medical diagnostics market, warranting close attention as developments unfold.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - Ynvisible Interactive Inc. (TSXV: YNV) (FSE: 1XNA) (OTCQB: YNVYF) (the "Company" or "Ynvisible"), a leader in printed e-paper display technology, is pleased to announce it has received a Letter of Intent ("LOI") from Sapphiros, a privately held consumer diagnostics company, to establish Ynvisible as an exclusive supplier of displays for certain lateral flow and molecular diagnostic tests manufactured by Sapphiros.
Key Highlights
- FDA regulatory pathway underway: Clinical studies of Sapphiros' Digital Lateral Flow tests are underway.
- Exclusive supply agreement expected: LOI outlines intention to enter into a three-year exclusive supply agreement.
- Commercial sales in 2026: Sales of Ynvisible displays to Sapphiros are underway and will accelerate throughout 2026.
- Expanding medical diagnostics market: This partnership represents Ynvisible's first commercial business in the large and rapidly growing global sector of Medical Diagnostics, with the Company expecting other customers in this market.
Ynvisible displays used in Sapphiros' diagnostic tests (right image credit: Sapphiros)
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4685/288084_ynimg1.jpg
To date, Ynvisible has supplied Sapphiros' companies with displays for laboratory testing and ongoing clinical studies related to platforms for respiratory and other rapid diagnostic tests, which are designed for both the point-of-care and direct-to-consumer markets. The LOI anticipates continued supply of Ynvisible products in support of the commercial launch of Sapphiros' products, once they receive regulatory approval.
This milestone builds on joint development work that began in 2024, during which Ynvisible engineered customized display solutions for integration into Sapphiros' diagnostics platforms.
Strategic Significance
The agreement represents an important step in Ynvisible's strategy to expand into high-volume medical and diagnostic applications, a market that continues to expand as healthcare systems increasingly adopt decentralized testing and rapid diagnostic technologies. Ynvisible's ultra-low power, thin, and flexible displays deliver clear, reliable results and are capable of operating without complex electronics, making Ynvisible's technology particularly well suited for these applications.
"This Letter of Intent represents an important step toward commercial deployment of Ynvisible's technology in next-generation diagnostic devices," said Ramin Heydarpour, CEO and Chairman of Ynvisible. "Our collaboration with Sapphiros demonstrates the performance and scalability of our printed e-paper displays in medical applications. As Sapphiros advances toward regulatory approvals and prepares for commercial launch, this relationship has the potential to create significant high-volume opportunities for Ynvisible."
"Sapphiros is committed to delivering innovations in diagnostics that enable global access and equitable health outcomes to patients and providers alike," said Mark Gladwell, CEO of Sapphiros. "Our partnership with Ynvisible empowers users of our diagnostic devices, whether in their homes, in clinical settings or elsewhere, with clear, visible results, offering confidence in understanding test outcomes."
About Ynvisible
Ynvisible is disrupting the low-cost and ultra-low-power display industry thanks to the latest advantages in sustainable electronics and roll-to-roll printing production. Ynvisible's printed e-paper displays are ideal for low-power and cost-sensitive applications, such as digital signage, smart monitoring labels for supply chain and logistics, visual indicators for medical and diagnostics, or retail labels and signage. Ynvisible has experience, know-how, and intellectual property in electrochromic materials, inks, and systems, and offers a mix of services, technology and products to brand owners developing smart objects and IoT products. Additional information on Ynvisible is available at www.ynvisible.com.
ON BEHALF OF THE BOARD OF DIRECTORS
Ramin Heydarpour
CEO and Executive Chairman
Ynvisible Interactive Inc.
For further information, please contact:
For Investor Relations:
+1 778-683-4324
ir@ynvisible.com
For Public Relations:
pr@ynvisible.com
About Sapphiros
Sapphiros, backed by KKR and Neoenta, is a privately held consumer diagnostics company. Sapphiros' portfolio of technologies and capabilities includes novel sample collection, next generation diagnostics, and extreme volume manufacturing, which help consumers and communities access important diagnostic results. For more information visit sapphiros.com.
For Media Relations:
press@sapphiros.com
Forward-Looking Statements
This news release contains certain statements that may be deemed "forward-looking" statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Ynvisible Interactive Inc. believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Ynvisible Interactive Inc. management on the date the statements are made. Except as required by law, Ynvisible Interactive Inc. undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288084
FAQ**
How might the partnership between Ynvisible Interactive Inc - Class A YNVYF and Sapphiros influence the growth of the medical diagnostics market in Vancouver and beyond?
What regulatory challenges might Ynvisible Interactive Inc - Class A YNVYF face while working with Sapphiros on their diagnostic tests, and how could these affect investment in the region?
In what ways does the technology developed by Ynvisible Interactive Inc - Class A YNVYF align with Vancouver's broader strategy for innovation in the healthcare and technology sectors?
How will Ynvisible Interactive Inc - Class A YNVYF's exclusive supply agreement with Sapphiros impact its operational capacity and market presence in Vancouver by the end of 2026?
**MWN-AI FAQ is based on asking OpenAI questions about Ynvisible Interactive Inc - Class A (OTC: YNVYF).
NASDAQ: YNVYF
YNVYF Trading
0.0% G/L:
$0.0875 Last:
45,025 Volume:
$0.0875 Open:
